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Abstract
Background: Endoscopic ultrasound is useful for obtaining high-resolution images of pancreaticobiliary diseases,
but is not readily available for physical checkups. In this study, we evaluated the safety and efficacy of single-session
esophagogastroduodenoscopy and endoscopic ultrasound in the detection of upper-gastrointestinal and
pancreaticobiliary diseases using a forward-viewing radial scan ultrasonic endoscope.
Methods: A total of 148 patients who were scheduled for upper-gastrointestinal screening using an endoscope
were prospectively included. All patients were examined by EUS in combination with EGD using a forward-viewing
radial scan ultrasonic endoscope. The primary endpoint was the safety of the procedures. The secondary endpoints
were the prevalence of diseases, the basal imaging capability of EUS, the procedure time, total dose of propofol,
and the correlation between background factors and the prevalence of pancreatic disease. The imaging capability
at each region was scored as 0 (invisible) to 2 (sufficient visualization to evaluate the organs).
Results: Intraoperative hypotension occurred as an adverse event of intravenous anesthesia in one patient. There
were 82 pancreaticobiliary findings and 165 upper-gastrointestinal findings (malignancy not included). Follicular
lymphoma of the intra-abdominal lymph nodes was detected in one patient. The mean imaging scores of each
section were 1.95 (pancreatic head and papilla), 2.0 (pancreatic body), 1.99 (pancreatic tail), and 1.89 (common bile
duct and gallbladder). Age, history of diabetes mellitus, and smoking history were significantly associated with the
prevalence of pancreatic diseases.
Conclusion: The simultaneous performance of EGD and EUS using a new ultrasonic endoscope is tolerable and
safe for upper-gastrointestinal and pancreaticobiliary screening.
Keywords: Endoscopic ultrasound, Diagnostic screening program, Pancreatic diseases, Biliary tract diseases
Background
It is often difficult to diagnose pancreaticobiliary dis-
eases, including malignant tumors such as pancreatic
cancer (PC) and biliary cancer (BC), which exhibit a
poor prognosis [1]. In particular, the early diagnosis of
PC is an urgent issue because the number of patients
with this condition increases each year. Recently, the
diagnosis and treatment of PC have advanced, but less
than 10% of patients are expected to survive for 5 years
after the diagnosis [2]. Patients with early-stage PC often
have no subjective symptoms, and most are diagnosed
incidentally. Thus, a screening test is required for pa-
tients with risk factors for PC; however, the optimal ap-
proach is not known.
The detection of premalignant lesions is one solution
for improving the survival of PC patients. Transabdom-
inal ultrasound is a non-invasive technique; however,
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screening of the pancreas is sometimes difficult [3].
Endoscopic ultrasound (EUS) is a novel technique for
screening of the pancreas, and is suitable for screening
high-risk individuals, and various studies have reported
the diagnostic performance of EUS [4–7]. However, it is
not a routine test, because it requires dedicated endo-
scopes, (e.g., endoscopes for radial and linear EUS) [8].
Recently, a new endoscopic ultrasonic processor (SU-
1; FUJIFILM, Tokyo, Japan) and radial scan ultrasonic
endoscope (EG-580UR; FUJIFILM, Tokyo, Japan)
equipped with a direct forward view, which enables the
simultaneous performance of esophagogastroduodeno-
scopy (EGD) and EUS. This endoscope enables the per-
formance pancreaticobiliary screening for patients who
undergo EGD. We conducted a prospective intervention
study evaluating the efficacy of the new ultrasonic endo-
scope in upper-gastrointestinal and pancreaticobiliary
screening.
Methods
Study design and sites
This was a prospective, interventional study conducted
at Okayama University Hospital from May 2017 to De-
cember 2018. This study was registered in the UMIN
protocol registration system (identification number:
UMIN000026627).
Participants
After receiving approval for the study from the institu-
tional review board, we recruited consecutive patients
who visited Okayama University Hospital to undergo
esophagogastroduodenoscopy (EGD).
The inclusion criteria were as follows:
1. Scheduled for screening EGD.
2. Over fifty years of age (because the prevalence of
PC increases with age, especially at ≥50 years of age
[9]).
3. The provision of voluntary written consent for
participation in this study.
The exclusion criteria were as follows:
1. ECOG performance status 3 or 4.
2. Suspected gastrointestinal bleeding.
3. A history of upper gastrointestinal surgery.
4. Allergy to propofol.
5. Received abdominal computed tomography (CT) or
magnetic resonance imaging (MRI) within the past
six months.
6. Judged by the attending physician to be ineligible
for inclusion in this study).
Instruments
Forward-viewing radial scan ultrasonic endoscope (EG-
580UR; FUJIFILM, Tokyo, Japan) instruments and an
endoscopic ultrasonic processor (SU-1; FUJIFILM,
Tokyo, Japan) were used. The EG-580UR has an outer
diameter of 11.4 mm, a unique capability of bending to
190°, a 2.8 mm working channel, and the super-CCD
image quality (Fig. 1). It also has a flexible imaging color
enhancement (FICE) mode that can maximize color dif-
ferences, such as vascular and mucosal patterns, without
the need for tissue staining [10]. EUS images were delin-
eated in standard B-mode, and the frequency was set at
7.5MHz.
Experimental methods
All procedures were carried out by six experienced
endosonographers (DU, HK, KM, YS, ST, and SM), who
met all of the following criteria: ≥8 years of endoscopy
experience, and ≥ 200 EUS examinations performed > 3
years. Procedures were performed under conscious sed-
ation with propofol (0.8 mg/kg induction dose and a 3–
5 mg/kg/h maintenance dose of 1% propofol using an in-
fusion pump, 0.5 mg/kg additional proper boluses). At
first, EGD was performed. After EGD screening, EUS
screening was performed to evaluate the pancreas, biliary
tract, and gallbladder. If abnormal findings were de-
tected, appropriate examinations or treatments were
provided.
Definitions and outcome measures
The primary endpoint was the safety of the procedures.
The secondary endpoints were the prevalence of pan-
creaticobiliary diseases that were detected by EUS, the
prevalence of upper-gastrointestinal diseases, the basal
imaging capability in the evaluation of the pancreatico-
biliary region, the procedure time, the total dose of pro-
pofol, and the correlation between the prevalence of
pancreatic diseases and patient background. To evaluate
the basal imaging capability, the pancreaticobiliary re-
gion was divided into four areas; pancreas head (includ-
ing papilla), pancreas body, pancreas tail, and biliary
tract including gallbladder. They were assessed and
assigned one of three scores: 0–2 points. “0” was
assigned when imaging was completely invisible for all
areas; “1” was assigned when the image was partially de-
lineated; and “2” was assigned when the visualization of
the target image was sufficient for the evaluation of the
organs (Table 3).
Partially visible (score “1”) was defined as any visible
delineation that did not meet the criteria for score “2”.
For example, if the junction of the superior mesenteric
vein (SMV), portal vein (PV), and splenic vein (SPV) was
unclear despite the pancreatic body parenchyma being
visible, the imaging score of the pancreatic body was “1”.
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As another example, if the region adjacent to the splenic
hilum and left kidney was unclear, despite the pancreatic
tail parenchyma being visible, the imaging score of the
pancreatic tail was “1”.
Statistical analysis
All statistical analyses were performed using the JMP
Pro 13.0 software program. Categorical data were evalu-
ated with the chi-squared test. P values of < 0.05 were
considered to indicate statistical significance. A multi-
variate logistic regression analysis was performed to
analyze associations between patient characteristics
(items that were associated with prevalence in a univari-
ate analysis; P < 0.05) and the prevalence of pancreatic
diseases.
Results
Patient characteristics
6033 patients underwent EGD screening within the time
frame, and 5885 patients were excluded because they
were < 50 years of age (n = 722), refused to participate
(n = 836), had a history of upper-gastrointestinal surgery
(n = 331), or had a history of abdominal CT or MRI
within the past six months (n = 3996). Finally, a total of
148 patients were included. The patient characteristics
are summarized in Table 1. One hundred six of the par-
ticipants were female (71.6%). Eleven participants (7.4%)
had one first- or second-degree blood relative with PC.
Fig. 1 a Shape of the EG-580UR. b: The diameter of the distal end of the 580UR is 11.4 mm, This device has a the unique ability of bending to
190°, and has a 2.8 mm working channel. c: A FICE image of esophagogastric junction obtained using the EG-580UR. d: A white light image of
the gastric body obtained using the EG-580UR. e: An EUS image of the pancreatic body obtained using the EG-580UR. Orange arrow indicates a
pancreatic cyst. f: An EUS image of the common bile duct obtained using the EG-580UR. Blue arrow indicates a bile duct stone
Table 1 Patient characteristics (n = 148)
Characteristics Value
Gender
Female 106 (71.6%)
Age, median (range) 69 (51–76)
Family history of PC 11 (7.4%)
History of diabetes mellitus 28 (23.3%)
Smoking status
Never 118
Former 21
Daily 9
Alcohol status
Daily drinker 44 (29.7%)
Daily alcohol consumption (g), median of drinker 7
Reason for EGD screening
Follow-up of chronic gastritis due to Helicobacter pylori 94
Follow-up of gastric polyp 16
Check for varices for patients with hepatitis 23
Check for reflux esophagitis 9
Abdominal discomfort 6
Post-cholecystectomy 6
PC pancreatic cancer; EGD esophagogastroduodenoscopy
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Twenty-eight (23.3%) participants had a history of dia-
betes mellitus. The most common reason for EGD
screening was follow-up of chronic gastritis due to Heli-
cobacter pylori. There were six post-cholecystectomy pa-
tients. Forty-four patients had undergone
transabdominal ultrasonography (AUS) in the past year.
Adverse events
One patient had hypotension (systolic blood pressure <
70mmHg) during the endoscopic procedure. This might
have been due to oversedation with propofol.
Hypotension was rapidly reversed following the adminis-
tration of ephedrine (4 mg). She recovered from
anesthesia without any further adverse events.
Prevalence of pancreaticobiliary disease
The prevalence of disease is shown in Table 2. There
were thirty-two patients with pancreatic cyst. The me-
dian cyst size was 5 mm. The largest was a 20-mm mul-
tilocular cyst, which was diagnosed as a branch duct
intraductal papillary mucinous neoplasm (IPMN) with-
out high-risk stigmata or worrisome features. All pa-
tients with pancreatic cysts were scheduled for follow-up
MRI at six months. Twenty-five patients were diagnosed
with early chronic pancreatitis, which had 3 to 4 minor
features of chronic pancreatitis, according to the Rose-
mont classification [11]. No patients had symptoms of
chronic pancreatitis. Fourteen patients had gallbladder
polyp (suspected cholesterol polyp). Nine patients had
adenomyomatosis and thirteen had asymptomatic gall-
bladder stones. These gallbladder lesions were scheduled
for follow-up AUS at six months. One patient had
asymptomatic common bile duct stone, and was treated
with endoscopic removal of the common bile duct stone
by endoscopic sphincterotomy. Other patients were
followed up with AUS, MRI or CT at one year at the pa-
tient’s request.
Forty-four patients had undergone AUS in the past
year. Sixteen of these patients were diagnosed with pan-
creatic disease (pancreatic cyst, n = 8; early chronic pan-
creatitis, n = 8) which was not detected by AUS in the
past year. Twelve of these patients were diagnosed gall-
bladder disease (adenomyomatosis, n = 7; gallbladder
stones, n = 5), that had already been diagnosed by AUS.
To date, 88 (59.5%) have already undergone follow-up
CT or MRI examinations. None of the patients showed
other pancreaticobiliary findings.
Prevalence of upper-gastrointestinal disease
As shown in Table 2, various findings were detected by
EGD screening. No patients had malignant features. In
56 patients (37.8%) cases, it was difficult to delineate the
lesser curvature of the gastric angle when pulling back
the scope because of the long distal end of the scope. In
these cases, the gastric angle could be evaluated in the
short scope position. All patients were scheduled for
follow-up EGD at one year. To date, 103 patients
(69.6%) have already undergone follow-up EGD using a
conventional EGD scope. Fortunately, no patients had
other findings on follow-up EGD.
Other diseases detected by EUS
There was one patient with follicular lymphoma of the
intra-abdominal lymph nodes. A swollen abdominal
lymph node (> 25mm) was pointed out, and EUS-guided
fine needle aspiration (EUS-FNA) was performed. EUS-
FNA revealed follicular lymphoma. She was followed
closely by hematologists.
Basal imaging capability of EUS
The mean imaging scores of each section were 1.95
(pancreatic head and papilla), 2.0 (pancreatic body), 1.99
(pancreatic tail), and 1.89 (common bile duct and gall-
bladder) (Table 3). The biliary imaging score of post-
cholecystectomy patients was without gallbladder im-
aging. There were no patients with score “0” in any
section.
Table 2 Prevalence of diseases
Pancreaticobiliary diseases
Pancreatic cysts 32 (21.6%)
Size of cyst, median, range (mm) 5 (2–20)
Early chronic pancreatitis* 25 (16.9%)
Gallbladder polyp 14 (9.5%)
Size of polyps, median range (mm) 4 (1–5)
Adenomyomatosis 9 (6.1%)
Gallbladder stone 13 (8.8%)
Common bile duct stone 1 (0.7%)
Upper-gastrointestinal diseases
Barrett’s esophagus 9 (6%)
Reflux esophagitis 41 (27.7%)
Candida esophagitis 1 (0.7%)
Esophageal papilloma 1 (0.7%)
Esophageal submucosal tumor 2 (1.4%)
Chronic gastritis 69 (46.6%)
Hyperplastic polyp 9 (6%)
Fundic gland polyp 14 (9.5%)
Gastric ulcer scar 1 (0.7%)
Gastric submucosal tumor 8 (5.4%)
Duodenal ulcer scar 8 (5.4%)
Duodenal submucosal tumor 2 (1.4%)
Others detected by EUS
Follicular lymphoma of intra-abdominal lymph nodes 1 (0.7%)
EUS endoscopic ultrasound
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Procedure times and total dose of propofol
The median procedure time was 22 min (EGD, 10min;
EUS, 11 min). The median total dose of propofol was
145 mg. A breakdown of these results is shown in
Table 4.
Correlation between the prevalence of pancreatic dis-
ease and patient background factors.
Age and a history of diabetes mellitus were extracted
as factors significantly associated with the prevalence of
pancreatic cysts in a univariate analysis. In the multivari-
ate logistic regression analysis, age was the only signifi-
cant factor. Sex, history of diabetes mellitus, smoking
history, and daily alcohol were extracted as factors sig-
nificantly associated with the prevalence of early chronic
pancreatitis. In the multivariate logistic regression ana-
lysis, history of diabetes mellitus and smoking history
were significant factors. Detailed data are shown in
Table 5.
Discussion
Small pancreaticobiliary tumors, such as PC and BC, are
difficult to diagnose because they have minimal symp-
toms in the early stages. However, advanced pancreati-
cobiliary cancers exhibit a poor prognosis. The 5-year
survival rate of PC patients is approximately 8%, and PC
is the fourth leading cause of cancer death worldwide
[12, 13]. The early diagnosis of PC is one solution to im-
proving the prognosis of PC, and various approaches
have been developed such as genetic screening of high-
risk patients [14, 15].
EUS is considered to be a sensitive device for the diag-
nosis of pancreaticobiliary diseases [16–18]. In particu-
lar, curved linear array EUS can obtain tissue by EUS-
guided fine needle aspiration (EUS-FNA), and has
become the scope that is predominantly used for EUS
examination. Meanwhile, radial scan EUS is used for
screening examinations, and can obtain transverse im-
ages of the pancreas, which provides objective evalua-
tions. However, these scopes are dedicated EUS devices,
and are unsuitable for medical check-ups.
On the other hand, EGD using a forward-viewing
endoscope and transabdominal ultrasound are com-
monly used in medical check-ups in Japan [19]. A
forward-viewing radial scan ultrasonic endoscope and
ultrasound processor (SU-1 and EG-580UR, respectively;
FUJIFILM, Tokyo, Japan) enable single-session screening
of the upper gastrointestinal tract and pancreaticobiliary
organ. EUS provides high-resolution images, and is an-
ticipated to be highly useful in the early diagnosis of
pancreaticobiliary tumors [16]. We conducted this study
to evaluate the efficacy of this device for the early diag-
nosis of pancreaticobiliary diseases, especially pancreatic
malignancies.
In the present study, we recruited 148 patients
scheduled for EGD screening (Table 1). We defined
the minimum age as 50 years, because the prevalence
of PC increases with age, especially in patients of ≥50
years of age [9]. As a result, a comparatively large
number of findings are detected by procedures (Table
2). EGD screening revealed various findings, including
reflux esophagitis, chronic gastritis, and gastrointes-
tinal benign tumors, but not malignancies. The image
quality of the CCD of the EG-580UR device is not
equivalent to that of the latest endoscopes. In fact, to
delineate the lesser curvature of the gastric angle
when pulling back the scope was difficult in 56 pa-
tients (37.8%). This constructional disadvantage
should be improved.
Table 3 Basal imaging capability of EUS
Score definition Mean
score2 1 0
Pancreatic head and
papilla
Duodenal papilla (the region of confluence of the pancreatic duct and bile ducts on the
duodenal muscularis), and the pancreas head (the region surrounded by the SMA and the
scope) are clearly visible
Partially
visible
Completely
invisible
1.95
Pancreatic body The pancreatic body (the region from the proximal parenchyma of the junction of SMV, PV
and SPV up to pancreatic tail) is clearly visible
Partially
visible
Completely
invisible
2
Pancreatic tail Pancreatic tail (the region adjacent to the splenic hilum and left kidney) is clearly visible Partially
visible
Completely
invisible
1.99
Common bile duct
and gallbladder
Common bile duct (from confluence of hepatic duct to pancreatic bile duct including
junction of cystic duct), and gallbladder (from neck to fundus) are serially visible
Partially
visible
Completely
invisible
1.89
EUS endoscopic ultrasound; SMA superior mesenteric artery; SMV superior mesenteric vein; PV portal vein; SPV splenic vein
Table 4 Procedure time, and total dose of propofol
Procedure time (min); median and range Total dose of propofol (mg); median and range
EGD EUS total 145 (30–350)
10 (5–25) 11 (10–29) 22 (15–45)
EGD esophagogastroduodenoscopy; EUS endoscopic ultrasound
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Various findings were detected by EUS screening. As
shown in Table 2, pancreatic cysts, which were detected
in 32 patients, were the most common finding.
Incidental pancreatic cysts are reported to be associated
with increased mortality, and follow-up is recommended
for patients in whom they are identified [20, 21]. IPMNs
are pancreatic cysts that are associated a risk of malig-
nancy; however, pancreatic cysts other than IPMNs may
cause pancreatic ductal carcinoma [22]. Laffan et al. re-
ported that the prevalence of unsuspected pancreatic cysts
detected by MDCT in an outpatient population was 2.6%,
which was correlated with increasing age and Asian race
[23]. There are also some reports on the prevalence of
pancreatic cysts on MRI imaging. De Jong reported that
the prevalence was 2.4%, while Lee et al. and Zhang et al.
reported that the prevalence was 13.5 and 19.6%, respect-
ively [24–26].
EUS is undoubtedly a superior tool for the diagnosis of
pancreatic diseases, including pancreatic cysts. Kamata
et al. reported that the EUS was superior to other imaging
modalities (e.g., CT or MRI) for the early detection of PC
in patients with IPMN [27]. Pausawasdi et al. reported
that EUS offered some benefits in the evaluation of pan-
creatic cyst [28]. They referred to the possibility of the
molecular and biomarker analysis of cyst fluid obtained by
EUS-FNA. Barresi et al. reported the efficacy of EUS-
through-the-needle biopsy in pancreatic cystic lesions;
however, this procedure is still in the investigational stage,
because it is associated with a risk of needle tract seeding
[29]. Additionally, contrast-enhanced EUS is reported to
be an effective tool for the diagnosis of pancreatic cysts
[30, 31]. We consider that EUS with high-resolution im-
aging can be a tool for identifying and qualitatively diag-
nosing pancreaticobiliary diseases.
Table 5 The correlation between the prevalence of pancreatic diseases and patient background
Pancreatic cyst (n = 32) Early chronic pancreatitis (n = 25)
Number Univariate Multivariate Number Univariate Multivariate
Odds ratio
(95%CI)
P
value
Odds ratio
(95%CI)
P
value
Odds ratio
(95%CI)
P
value
Odds ratio
(95%CI)
P
value
Age
≥ 70 (n = 68) 22
(32.4%)
3.35 (1.45–7.71) 0.0035 3.18 (1.36–7.38) 0.0073 12
(17.7%)
1.10 (0.47–2.61) 0.8212
< 70 (n = 80) 10
(12.5%)
13
(16.3%)
Sex
Male (n = 42) 9
(21.4%)
0.98 (0.41–2.35) 0.9714 14
(33.3%)
4.32 (1.76–10.6) 0.0008 2.08 (0.65–6.66) 0.2147
Female (n = 106) 23
(21.7%)
11
(10.4%)
Family history of PC
Yes (n = 11) 4
(36.4%)
2.22 (0.61–8.14) 0.217 2
(18.2%)
1.10 (0.22–5.44) 0.9055
No (n = 137) 28
(20.4%)
23
(16.8%)
History of diabetes mellitus
Yes (n = 28) 10
(35.7%)
2.47 (1.01–6.09) 0.0442 2.23 (0.88–5.65) 0.0921 10
(35.7%)
3.89 (1.51–9.99) 0.0032 3.78 (1.33–10.8) 0.0128
No (n = 120) 22
(18.3%)
15
(12.5%)
Smoking history
Yes (n = 30) 6 (20%) 0.88 (0.33–2.39) 0.8091 12
(40%)
5.38 (2.12–13.7) 0.0002 3.54 (1.04–12) 0.043
No (n = 118) 26
(22%)
13
(11%)
Alcohol status
Daily (n = 44) 11
(25%)
1.32 (0.57–3.03) 0.5161 13
(29.6%)
3.22 (1.33–7.78) 0.0075 1.06 (0.34–3.3) 0.9223
Never or occasional
(n = 104)
21
(20.2%)
12
(11.5%)
PC pancreatic cancer
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Our result showed that the prevalence of pancreatic
cysts was 21.6%, which was clearly higher in comparison
to previous reports. This contradictory finding have been
due to the fact that our cohort consisted of patients of
≥50 years of age. Actually, an autopsy study revealed that
24.3% of patients (most patients were ≥ 65 years of age)
had pancreatic cysts [32]. Fortunately, there were no ma-
lignant findings, such as high-risk stigmata or IPMNs
with worrisome features, and the patients with cysts of
> 5 mm in size were scheduled for follow-up MRI at six
months. In our data, age and a history of diabetes melli-
tus were significantly associated with the prevalence of
pancreatic cysts (Table 4).
Chronic pancreatitis is a risk factor for PC [33]. Re-
cently, the early diagnosis of chronic pancreatitis with
EUS has gained attention; however, the extent to which
early chronic pancreatitis is associated with pancreatic
carcinogenesis is still unclear [11, 34]. In our study, the
prevalence of early chronic pancreatitis was 16.9%; this
was related to a history of diabetes mellitus and smoking
history (Tables 2 and 4). This result is in line with previ-
ous reports, and serves as a useful reference for identify-
ing high-risk patients [24, 34–36]. A family history of PC
is a known risk factor for PC [37, 38]. There was no sig-
nificant association between a family history of PC and
the prevalence of pancreatic disease in this study. There
may be some reasons for this controversial result. Canto
et al. reported that individuals with three or more blood
relatives with PC, including at least one first-degree rela-
tive, should be considered for screening [38]. In our
study, there were 11 patients with only one affected first
or second-degree blood relative. Additionally, the rela-
tively small number of patients may have affected the
result.
One patient had enlarged intra-abdominal lymph
nodes, and was diagnosed with follicular lymphoma by
EUS-FNA and 18-fluoro-2-deoxy-D-glucose positron
emission tomography (FDG-PET). She was referred to a
hematology specialist, and followed closely without
chemotherapy.
The imaging capability of EUS was generally good
(Table 3). However, these procedures were performed by
experienced endosonographers. The technique of EUS
imaging is sometimes difficult, and the diagnostic per-
formance of EUS is operator-dependent. Increasing the
number of endosonographers is also necessary to facili-
tate the early diagnosis of pancreaticobiliary diseases.
The screening method using the EG-580UR device is a
little different from the traditional method using an or-
dinary EUS scope, especially with regard to duodenal
manipulation, because this new scope has a slim distal
end (11.4 mm) and a small bending radius. At first, this
difference perplexed us; however, all operators soon got
used to it. Actually, the imaging capability of EUS was
generally good, and the procedure time was tolerable
(Tables 3 and 4). Recently, curved linear array EUS
scope is widely used. Radial scan EUS scope provides
understandable organ image with 360°scanning range,
however it cannot collect tissue samples. Kaneko et al.
reported that there was not a significant difference be-
tween the imaging capability of radial scan scope and
curved linear array scope, however, both scope have pros
and cons [39]. They reported radial scan scope was su-
perior in the delineation of the major duodenal papilla
and gallbladder. Front-viewing radial scan scope may be
able to expand options for scope choice. Additionally,
this scope and single-session EGD and EUS method may
widen the training opportunities for novices. Increasing
experts of EUS procedure using forward-viewing radial
scan EUS scope may be conductive to improve pancrea-
ticobiliary diseases.
The present study was associated with some limita-
tions. The accuracy of the EUS findings was unclear be-
cause some participants did not undergo screening with
other modalities (e.g., CT or MRI). Most patients were
also scheduled for follow-up AUS, MRI or CT at six
months; however, some patients who had no pancreati-
cobiliary findings did not wish to undergo the examin-
ation because of the high cost. Fortunately, there were
no other pancreaticobiliary findings in 88 patients
(59.5%) who—at the time of writing—have already
undergone follow-up using AUS, CT or MRI. Addition-
ally, the accuracy of EGD was still unclear. To date, 103
patients (69.6%) have already undergone follow-up EGD
using a conventional EGD scope, and no other gastro-
intestinal findings were identified in follow-up EGD. It
was unclear whether EUS was superior to other modal-
ities; however, some patients were diagnosed with pan-
creatic diseases that could not be detected by post-AUS.
This result proved the high sensitivity of EUS in the
diagnosis of pancreatic lesions. These subjects should be
evaluated in a future analysis with comparative design
including large number of participants.
In this study, there was only one adverse event, which
might have been caused by oversedation. We were con-
cerned about the risk of increasing the dose of propofol;
thus, we excluded patients with an ECOG performance
status of 3 or 4. However, most procedures were com-
pleted within 30 min as a result. This might have been
due to the normal EUS findings in most patients.
Conclusion
In conclusion, a forward-viewing radial scan ultrasonic
endoscope, the EG-580UR, was a novel tool for screen-
ing of gastrointestinal and pancreaticobiliary diseases.
Further developments in manipulation and image quality
are expected, which may help to improve the prognosis
of pancreaticobiliary diseases.
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